CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 526 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
EHT 5372
CAS:EHT 5372 inhibits DYRK kinases; IC50: 0.22-221 nM for DYRK1A/B, DYRK2/3, CLK1/2/4, GSK-3α/β.Formula:C17H11Cl2N5OSColor and Shape:SolidMolecular weight:404.27CDK7-IN-14
CAS:CDK7-IN-14, a potent CDK7 inhibitor from pyrimidines, may treat transcriptionally dysregulated cancers (CN114249712A).Formula:C22H24F3N6OPPurity:99.48%Color and Shape:SolidMolecular weight:476.43LDC3140
CAS:LDC3140 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7).Formula:C23H33N7OPurity:98%Color and Shape:SolidMolecular weight:423.55CDK8-IN-3
CAS:CDK8-IN-3 is an inhibitor of CDK8.Formula:C22H23N5O2Purity:98%Color and Shape:SolidMolecular weight:389.45CDK-IN-11
CAS:CDK-IN-11, a heterocyclic compound, promotes cardiomyocyte maturation [1].Formula:C25H21BrN4O2Color and Shape:SolidMolecular weight:489.36ML 315 hydrochloride
CAS:<p>ML 315, a selective dual inhibitor targeting CDK (Cyclin-Dependent Kinase) and DYRK (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase) with IC50 values of 68 nM and 282 nM, respectively, is utilized in research pertaining to cancer and neurological diseases [1].</p>Formula:C18H14Cl3N3O2Color and Shape:SolidMolecular weight:410.682Riviciclib
CAS:Riviciclib, a CDK inhibitor (CDK9/T1, CDK4/D1, CDK1/B), has IC50s: 20, 63, 79 nM respectively, and fights cisplatin-resistant tumors.Formula:C21H20ClNO5Purity:98%Color and Shape:SolidMolecular weight:401.84CDK9-IN-19
CAS:CDK9-IN-19: Potent CDK9 inhibitor, anti-cancer, moderate pharmacokinetics, low hERG impact, effective in AML research.Formula:C26H22F2N4O5Color and Shape:SolidMolecular weight:508.47Senexin A hydrochloride
CAS:Senexin A hydrochloride functions as a selective inhibitor of CDK8/19, with an IC 50 of 280 nM for CDK8, and specifically inhibits p21-induced transcription without affecting other biological effects of p21. Additionally, it suppresses CMV-GFP induction and the stimulatory activity of the consensus NF-κB-dependent promoters [1] [2].Formula:C17H15ClN4Color and Shape:SolidMolecular weight:310.78(S)-Cdc7-IN-18
CAS:'(S)-Cdc7-IN-18 from patent WO2020239107A1 inhibits CDC7, curbing MCM2 and tumor growth.'Formula:C19H21N5OSColor and Shape:SolidMolecular weight:367.47SHP2/CDK4-IN-1
CAS:SHP2/CDK4-IN-1: dual inhibitor, oral, potent (IC50: SHP2 4.3 nM, CDK4 18.2 nM), hinders TNBC growth, strong antitumor effects in mice.Formula:C33H35ClF2N10OSColor and Shape:SolidMolecular weight:693.21Inixaciclib
CAS:Inixaciclib is a potent CDK inhibitor, can be used to research anticancer.Formula:C26H30F2N6OColor and Shape:SolidMolecular weight:480.55SZ-015268
CAS:SZ-015268: CDK7 inhibitor, IC50=23.56 nM; hinders HCC70, OVCAR-3, HCT116, HCC1806 cell growth; strong anti-tumor effect.Formula:C25H38N8O3Color and Shape:SolidMolecular weight:498.62CDK4/6-IN-15
CAS:CDK4/6-IN-15: Oral, selective CDK4/6 inhibitor, halts cancer cell growth, G1 arrest, suppresses Rb phosphorylation.Formula:C21H27FN8SColor and Shape:SolidMolecular weight:442.56Cdc7-IN-12
CAS:Cdc7-IN-12, a sub-1 nM CDC7 inhibitor, may aid cancer research; hinders COLO205 cell growth (IC50: 100-1000 nM).Formula:C16H14N2O2SColor and Shape:SolidMolecular weight:298.36Xylocydine
CAS:Xylocydine is a novel Cdk inhibitor that induces apoptosis in HCC, suppresses tumor growth, and is non-toxic to other tissues.Formula:C12H14BrN5O5Color and Shape:SolidMolecular weight:388.17CDK/HDAC-IN-3
CAS:CDK/HDAC-IN-3 is an orally active dual inhibitor of HDACs and CDKs, offering potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2, and HDAC3,Formula:C24H18Cl2N6O3Purity:98%Color and Shape:SolidMolecular weight:509.34Cdk4 Inhibitor
CAS:PD 0332991, an unsymmetrical indolocarbazole compound, is cell-permeable and exhibits antiproliferative effects by functioning as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk4/D1 (IC 50 = 76 nM). Although it can inhibit other Cdks, such as Cdk2/E and Cdk1/B, effectiveness requires higher concentrations (IC 50 = 520 nM and 2.1 µM, respectively) and demonstrates minimal activity against CaMKII, PKA, or GSK-3β (IC 50 ≥ 12.4 µM). PD 0332991 efficiently inhibits tumor cell growth in HCT-116 and NCI-H460 cell lines with an IC 50 < 3.0 µM, primarily through blocking Rb phosphorylation and inducing G1 cell cycle arrest.Formula:C20H10BrN3O2Color and Shape:SolidMolecular weight:404.2Nε-(1-Carboxyethyl)-L-lysine
CAS:Nε-(1-Carboxyethyl)-L-lysine (CEL) is an advanced glycation end-product (AGE). Exposure to CEL reduces glutamate uptake and S100B secretion in the hippocampus.Formula:C9H18N2O4Color and Shape:SolidMolecular weight:218.25Lerociclib
CAS:<p>Lerociclib (G1T38) is a CDK4/6 inhibitor with anticancer and antitumor activities, inhibiting CDK4/CyclinD1 and CDK6/CyclinD3.</p>Formula:C26H34N8OPurity:99%Color and Shape:SolidMolecular weight:474.6
